Allarity's stock falls after saying enrollment in two clinical trials is slow
Shares of Allarity Therapeutics Inc. (ALLR) plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to enroll enough patients in Phase 2 studies for Ixempra and senoparib, citing the impact of the pandemic on staffing for clinical-trial sites. The company is testing Ixempra as a treatment for metastatic breast cancer and stenoparib for ovarian cancer. Allarity's stock is down 75.0% this year, while the S&P 500 has gained 4.0%.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 28, 2023 08:35 ET (12:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.